Clinical trial
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00004204 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00004204 |
|---|---|
| Title | Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma |
| Official title | A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide |
| Start date | Feb 1, 2000 |
| First posted | Jul 18, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: